Relief by botulinum toxin of voiding dysfunction due to benign prostatic hyperplasia: Results of a randomized, placebo-controlled study

Urology

Volumn 62, Issue 2, 2003, Pages 259-264

  Maria, Giorgio ^a   Brisinda, Giuseppe ^b   Civello, Ignazio Massimo ^b   Bentivoglio, Anna Rita ^b   Sganga, Gabriele ^b   Albanese, Alberto ^b  

^a FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A; PROSTATE SPECIFIC ANTIGEN; SODIUM CHLORIDE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FOLLOW UP; HUMAN; MALE; MICTURITION DISORDER; ORGAN SIZE; PRIORITY JOURNAL; PROSTATE; PROSTATE HYPERTROPHY; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; URINE FLOW RATE; URINE VOLUME;

EID: 0042624721     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(03)00477-1     Document Type: Article

References (30)

1. Oesterling J.E. Benign prostatic hyperplasia medical and minimally invasive treatment options . N Engl J Med. 332:1995;99-109.
2. Roehrborn C.G., Bartsch G., Kirby R., et al. Guidelines for the diagnosis and treatment of benign prostatic hyperplasia a comparative, international overview . Urology. 58:2001;642-650.
3. McConnell J.D., Bruskewitz R., Walsh P., et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N Engl J Med. 338:1998;557-563.
4. Walsh P.C. Treatment of benign prostatic hyperplasia. N Engl J Med. 335:1996;586-587.
5. Barry M.J., Roehrborn C.G. Benign prostatic hyperplasia. BMJ. 323:2001;1042-1046.
6. Clifford G.M., Farmer R.D. Medical therapy for benign prostatic hyperplasia a review of the literature . Eur Urol. 38:2000;2-19.
7. de la Rosette J.J., Alivizatos G., Madersbacher S., et al. EAU guidelines on benign prostatic hyperplasia (BPH). Eur Urol. 40:2001;256-263.
8. Lu-Yao G.L., Barry M.J., Chang C.H., et al. Transurethral resection of the prostate among Medicare beneficiaries in the United States time trends and outcomes . Urology. 44:1994;692-698.
9. McConnell JD, Barry MJ, and Bruskewitz RC: Benign prostatic hyperplasia: diagnosis and treatment. Agency for Health Care Policy and Research. Clin Pract Guidel Quick Ref Guide Clin 1994:1-17.
10. Boyle P., Robertson C., Manski R., et al. Meta-analysis of randomized trials of terazosin in the treatment of benign prostatic hyperplasia. Urology. 58:2001;717-722.
11. Lepor H., Williford W.O., Barry M.J., et al. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. N Engl J Med. 335:1996;533-539.
12. Narayan P., Lepor H. Long-term, open-label, phase III multicenter study of tamsulosin in benign prostatic hyperplasia. Urology. 57:2001;466-470.
13. Lepor H. Role of long-acting selective alpha-1 blockers in the treatment of benign prostatic hyperplasia. Urol Clin North Am. 17:1990;651-659.
14. Brisinda G., Maria G., Bentivoglio A.R., et al. A comparison of injections of botulinum toxin and topical nitroglycerin ointment for the treatment of chronic anal fissure. N Engl J Med. 341:1999;65-69.
15. Maria G., Brisinda G., Bentivoglio A.R., et al. Anterior rectocele due to obstructed defecation relieved by botulinum toxin. Surgery. 129:2001;524-529.
16. Phelan M.W., Franks M., Somogyi G.T., et al. Botulinum toxin urethral sphincter injection to restore bladder emptying in men and women with voiding dysfunction. J Urol. 165:2001;1107-1110.
17. Schurch B., Stohrer M., Kramer G., et al. Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients a new alternative to anticholinergic drugs? Preliminary results . J Urol. 164:2000;692-697.
18. Maria G., Destito A., Lacquaniti S., et al. Relief by botulinum toxin of voiding dysfunction due to prostatitis. Lancet. 352:1998;625.
19. Zermann D., Ishigooka M., Schubert J., et al. Perisphincteric injection of botulinum toxin type A a treatment option for patients with chronic prostatic pain? Eur Urol. 38:2000;393-399.
20. Doggweiler R., Zermann D.H., Ishigooka M., et al. Botox-induced prostatic involution. Prostate. 37:1998;44-50.
21. Barry M.J., Fowler F.J. Jr, O'Leary M.P., et al. Correlation of the American Urological Association symptom index with self-administered versions of the Madsen-Iversen, Boyarsky and Maine Medical Assessment Program symptom indexes. J Urol. 148:1992;1558-1563.
22. Barry M.J., Fowler F.J. Jr, O'Leary M.P., et al. The American Urological Association symptom index for benign prostatic hyperplasia. J Urol. 148:1992;1549-1557.
23. Barry M.J., Girman C.J., O'Leary M.P., et al. Using repeated measures of symptom score, uroflowmetry and prostate specific antigen in the clinical management of prostate disease. J Urol. 153:1995;99-103.
24. Murray E., Davis H., Tai S.S., et al. Randomised controlled trial of an interactive multimedia decision aid on benign prostatic hyperplasia in primary care. BMJ. 323:2001;1-6.
25. Kaplan S.A., Holtgrewe H.L., Bruskewitz R., et al. Comparison of the efficacy and safety of finasteride in older versus younger men with benign prostatic hyperplasia. Urology. 57:2001;1073-1077.
26. McConnell J.D. Benign prostatic hyperplasia. J Urol. 152:1994;459-460.
27. Gkonos P.J., Krongrad A., Roos B.A. Neuroendocrine peptides in the prostate. Urol Res. 23:1995;81-87.
28. Doehring C.B., Sanda M.G., Partin A.W., et al. Histopathologic characterization of hereditary benign prostatic hyperplasia. Urology. 48:1996;650-653.
29. Farnsworth W.E. Prostate stroma physiology . Prostate. 38:1999;60-72.
30. Ruggieri M.R., Colton M.D., Wang P., et al. Human prostate muscarinic receptor subtypes. J Pharmacol Exp Ther. 274:1995;976-982.